Global Kidney Cancer or Renal Cancer Market Growth (Status and Outlook) 2024-2030

Global Kidney Cancer or Renal Cancer Market Growth (Status and Outlook) 2024-2030

Kidney cancer, also known as renal cancer, refers to cancer that originates in the kidneys. The kidneys are two bean-shaped organs located on either side of the spine, responsible for filtering blood, removing waste, and producing urine. Kidney cancer can take several forms, but the most common type is renal cell carcinoma (RCC).

The global Kidney Cancer or Renal Cancer market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Kidney Cancer or Renal Cancer Industry Forecast” looks at past sales and reviews total world Kidney Cancer or Renal Cancer sales in 2022, providing a comprehensive analysis by region and market sector of projected Kidney Cancer or Renal Cancer sales for 2023 through 2029. With Kidney Cancer or Renal Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Kidney Cancer or Renal Cancer industry.

This Insight Report provides a comprehensive analysis of the global Kidney Cancer or Renal Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Kidney Cancer or Renal Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Kidney Cancer or Renal Cancer market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kidney Cancer or Renal Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kidney Cancer or Renal Cancer.

United States market for Kidney Cancer or Renal Cancer is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Kidney Cancer or Renal Cancer is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Kidney Cancer or Renal Cancer is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Kidney Cancer or Renal Cancer players cover Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Kidney Cancer or Renal Cancer market by product type, application, key players and key regions and countries.

Segmentation by Type:
Targeted Therapy
Chemotherapy
Immunotherapy

Segmentation by Application:
Hospital
Pharmacy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Targeted Therapy
Chemotherapy
Immunotherapy

Segmentation by Application:
Hospital
Pharmacy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Pfizer
GSK

Please note: The report will take approximately 2 business days to prepare and deliver.